TOI Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 0.76
- P/S (TTM)
- 0.94
- EV/EBITDA
- 8.53
Profitability & growth
- ROE (TTM)
- -652.0%
- Operating margin
- -4.4%
- Revenue growth YoY
- 41.2%
- Dividend yield
- —
- Beta
- 0.42
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Oncology Institute Inc
Company profileOncology Institute Inc (ticker: TOI) is a leading healthcare organization focused on revolutionizing cancer care through its extensive network of specialized clinics and innovative treatment methodologies. By harnessing advanced technologies and personalized care strategies, the company aims to significantly improve patient outcomes while emphasizing clinical trials and partnerships with premier research institutions. Positioned to capitalize on the growing demand for advanced cancer therapies, TOI benefits from a solid pipeline and a wealth of oncology expertise, presenting a compelling…
Classification
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 18000 STUDEBAKER ROAD, CERRITOS, CA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer